Tumori: l'immunoterapia pre-intervento rivoluziona le cure. Convegno a Napoli [Oncologia-Ematologia]

Dal melanoma al tumore del polmone, dal cancro al seno triplo negativo a quello del colon-retto e della vescica: sono sempre più numerosi i tumori per cui la somministrazione dell’immunoterapia neoadiuvante, cioè del trattamento prima dell’intervento chirurgico, mostra evidenze di maggiore efficacia. Questa nuova evoluzione dell’immunoterapia è al centro della seconda edizione di “I.N.N.O.VA.T.E. – International Neoadjuvant Immunotherapy Across Cancers”, al via oggi, e fino a domani, a Napoli.

Read More

Basalioma, con immunoterapico “locale” possibile remissione [Oncologia-Ematologia]

Dopo aver dimostrato la sua efficacia nel melanoma, il farmaco immunoterapico Daromun, iniettabile direttamente nella massa tumorale, sembra essere promettente anche nel trattamento dei tumori cutanei più diffusi: il carcinoma basocellulare e quello squamocellulare. I risultati preliminari di uno studio di fase II verranno discussi domani a Napoli in occasione della seconda edizione del congresso INNOVATE – International Neoadjuvant Immunotherapy Across Cancers

Read More

Cutaneous non-volar melanoma dermoscopy and histopathology correlation: a systematic review protocol

Introduction
Dermoscopy has a proved validity in the diagnosis of cutaneous melanoma, which is one of the most aggressive forms of skin cancer. Although some studies have demonstrated a relationship between specific dermoscopic and pathologic melanoma features, there is no solid evidence allowing reliable conclusions. This study will evaluate the evidence regarding this association.

Methods and analysis
Observational studies eligible for our systematic review will enrol adults with histological cutaneous non-volar melanoma diagnosis and with dermoscopy image analysis. We will search the following databases: PubMed, Embase, Web of Science, MEDLINE and Cochrane Library. We will not impose any language or date restrictions. Outcomes of interest include the association of at least one of the melanoma dermoscopy features (irregular pigmentation, blue-white veil, atypical network, multicomponent pattern, atypical dots and/or globules, regression, peripheral tan structureless area, negative network, shiny white structures, atypical vessels and streaks/pseudopods), with melanoma Breslow index or other histopathology characteristics (melanoma subtype, mitotic index and presence of ulceration). Two reviewers will independently screen and search results, extract data from eligible studies and assess risk of bias. The evidence derived by this study will elucidate the possible link between melanoma dermoscopy and histopathology. If we could predict melanoma thickness based on dermoscopy, we would be able to anticipate melanoma treatment with impact on survival.

Ethics and dissemination
Ethical approval is not required because this is a literature-based study. It will be published in scientific Pubmed indexed open access journals to ensure its accessibility.

PROSPERO registration number
CRD42024564919.

Read More

Error in Display of Author Name

The Original Investigation titled “Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma,” published online April 9, 2025, was corrected because there was a display issue with author surname Olofsson Bagge in PubMed. This article was corrected online.

Read More